Outsourced Pharma Capacity Update
The AAV Curator® adherent platform has been used to manufacture more than 450 Phase I and II clinical batches, spanning over 17 years and covering a variety of serotypes and indications. In this webinar, Andelyn Biosciences' Sarah Bergman, Senior Scientist, discusses the approach used to assess the robustness of the adherent platform and identify potential critical process parameters leveraging compiled historical data generated at each process step of GMP production.
The AAV Curator® adherent platform has been used to manufacture more than 450 Phase I and II clinical batches, spanning over 17 years and covering a variety of serotypes and indications. In this webinar, Andelyn Biosciences' Sarah Bergman, Senior Scientist, discusses the approach used to assess the robustness of the adherent platform and identify potential critical process parameters leveraging compiled historical data generated at each process step of GMP production.
The AAV Curator® adherent platform has been used to manufacture more than 450 Phase I and II clinical batches, spanning over 17 years and covering a variety of serotypes and indications. In this webinar, Andelyn Biosciences' Sarah Bergman, Senior Scientist, discusses the approach used to assess the robustness of the adherent platform and identify potential critical process parameters leveraging compiled historical data generated at each process step of GMP production.